The "Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of COVID-19 Pandemic. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2021-2025" report has been added to ResearchAndMarkets.com's offering.
The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? This report provides a detailed analysis.
Circulating Tumor Cells? Cell-Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.
GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market.
New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase.
The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.
Liquid Biopsy Recent Developments
Liquid Biopsy NGS Panels - Diverse Test Claims
CMS Colon Cancer Screening Memo Bodes Well for Assays
Natera Liquid Biopsy Test Coverage to Expand
Freenome Closes Financing to Support Early Cancer Detection Trial
C$2.6M Liquid Biopsy Initiative
NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
Liquid Biopsy Shows Promise as Screen for Cancers
Inivata launches RaDaRT for the detection of residual disease and recurrence
Liquid Biopsy Assay Detects 50+ Types of Cancer
Liquid Biopsy Study Confirms Concordance with Tissue Biopsy
Guardant Health Liquid Biopsy Expands Medicare Coverage
Aethlon Medical Lands Grant for Exosome Isolation Device
Biolidics to Develop Liquid Biopsy Breast Cancer Test
Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
Exact Sciences buys Genomic Health
Multi-Gene Liquid Biopsy Breast Cancer Panel
Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
Thrive to Develop Earlier Detection of Multiple Cancer Types
Guardant Health Liquid Biopsy Test to be Covered by EviCore
Liquid biopsy combines Illumina's 'ultradeep' sequencing with Grail's machine learning
Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
Natera Commercializes Tumor Whole Exome Sequencing from Plasma
Sienna Buys Liquid Biopsy & Exosome Isolation Technology
Inivata Completes £39.8M Series B Funding Round
Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
Biodesix Acquires Integrated Diagnostics
Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
Bio-Techne to Acquire Exosome Dx for Up to $575M
GRAIL Announces Data on Detection of Early-Stage Lung Cancers
Precision for Medicine Acquires ApoCell
NeoGenomics to Acquire Genoptix for Cash, Stocks
PGDx Liquid Biopsy Assay to be Used in Cancer Drug Study
Liquid...
Read More
(All Rights Reserved)